



August 21, 2018

Phillip Steindel, PhD
Review Editor
JoVE
One Alewife Center, Suite 200
Cambridge, MA 02140
Tel: 617-674-1888

RE: JoVE58937 manuscript submission

Dear Dr. Steindel:

Thank you very much for your email communication on August 15, 2018 regarding our JoVE58937 manuscript, entitled "Tumor Treating Fields Therapy: Cell Biology, Electric Field Modeling, and Clinical Application". We have made changes in the manuscript by removing commercial identifiers and replaced it with generic terms. Specifically, NovoTTF-100A<sup>TM</sup> and Optune<sup>TM</sup> are now described as first and second generation TTFields devices, respectively. Furthermore, NovoTAL<sup>TM</sup> is now named as the treatment planning software for TTFields.

We hope that these changes are satisfactory and thank you very much for your consideration. We look forward to hearing from you.

Sincerely yours,

Eric T Wong, MD

**Associate Professor of Neurology** 

Harvard Medical School

Director, Brain Tumor Center & Neuro-Oncology Unit Beth Israel Deaconess Medical Center

Director, Neuro-Oncology Fellowship Program Beth Israel Deaconess Medical Center

Member, Neuro-Oncology Protocol Committee Dana Farber/Harvard Cancer Center